MS FATIMA NADEEM MIRZA (Orcid ID : 0000-0003-1299-6258)

MS SARA YUMEEN (Orcid ID : 0000-0002-5729-5909)

Article type : Research Letter

Article type: Research Letter

Title: The Epidemiology of Malignant Melanoma, Squamous Cell Carcinoma, and Basal Cell Carcinoma in the United Kingdom from 2004-2014: A Population-Based Cohort Analysis using the Clinical Practice Research Datalink

F. N. Mirza,^{1,2} S. Yumeen¹ and F. M. Walter²

¹Department of Dermatology, Yale School of Medicine, New Haven, CT

²Department of Public Health and Primary Care, University of Cambridge, Cambridge, England

Corresponding author:

Fatima N. Mirza MPH

Email: fatima.mirza@yale.edu

Funding sources: No funding sources to report for this manuscript.

Conflict of Interest Statement: The authors have no conflicts of interest to declare.

Manuscript word count: 770

References:

Figures: 0

Supplementary figures: 0

Tables: 1

Supplementary tables: 0

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/BJD.19542](https://doi.org/10.1111/BJD.19542)

This article is protected by copyright. All rights reserved

To the editor:

Skin cancers, including malignant melanoma and keratinocyte skin cancers, are the most common malignancy in the United Kingdom (UK), and global incidence is increasing rapidly¹. While malignant melanoma (MM) accounts for most skin cancer deaths, keratinocyte skin cancers, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), comprise up to 95% of skin cancer cases in the UK^{2,3}. Studies on trends in MM incidence and survival have been conducted using Scottish, Northern Irish, and English and Welsh data⁴. Data for keratinocyte skin cancers has historically been unreliable and under-reported due to the United Kingdom and Ireland Association of Cancer Registries rule to only report the first SCC or BCC per patient when a substantial proportion of patients develop multiple tumours. For the few studies on SCC and/or BCC, trends are geographically limited in scope to a particular region or, when considering the whole of the UK, report trends from a limited time period^{5,6}. In 2013, changes in England's national cancer registry resulted in nationalized and automated SCC and BCC registration. While this has improved reporting of keratinocyte skin cancer incidence in England and will allow tracking and analysis of future trends, knowledge of epidemiologic trends in SCC and BCC before this time, and reporting for the rest of the UK, remain inconsistent.

The primary care Clinical Practice Research Datalink (CPRD) provides the opportunity to characterize the trends of both MM and keratinocyte skin cancers as well as their primary care burden prior to 2013. Here we describe epidemiologic trends of MM, SCC and BCC over a ten-year period (2004-2014) using CPRD GOLD data (Independent Scientific Advisory Committee protocol number 16_136). CPRD collects de-identified patient data from a network of GP practices across the UK. Primary care data are linked to a range of other health related data to provide a longitudinal, representative UK population health dataset. The data encompass 50 million patients, including 14 million currently registered patients. Additional methods and results are available upon direct request.

In our cohort there were 12057, 17614, and 80854 patients in the whole of the UK living with MM, SCC, or BCC respectively. The prevalence of MM was 0.3%, SCC was 0.4% and BCC was highest at 1.8%. Over the 10-year study period there was a 36% increase in the age-adjusted incidence MM, a 34% increase in SCC, and a 21% increase of BCC. Sex-stratified incidence per 100,000 PY age-adjusted (standard error) for 2004 then 2014 was: for MM, 15.8 (0.9) to 26.4 (1.0) for men and 22.4 (1.1) to 25.5 (1.0) for women; for SCC, 48.2 (1.4) to 66.0

(1.6) for men and 25.4 (1.2) to 32.6 (1.2) for women; and for BCC, 161.2 (2.6) to 201.1 (2.7) for men and 124.0 (2.5) to 143.8 (2.5) for women. A logistic regression model, with mixed random-effects parameters for patient ID and practice, demonstrated, for the keratinocyte skin cancers, older patient age, male patient sex, and more recent year of diagnosis was associated with an incident case. In comparison to England, patients in Wales were more likely, and those in Scotland or Northern Ireland were less likely, to be diagnosed with a new BCC, whereas the opposite was true for SCC. For MM, younger patient age, female patient sex, and more recent year of diagnosis were associated with an incident case; patients in Wales were less likely to have a new MM diagnosis compared to those in England. Amongst patients for whom Office of National Statistics death registration data were available, all-cause mortality rates were 3.63 deaths/1,000 person-years for MM, highest for SCC with 7.02 deaths/1,000 person-years, and 3.04 deaths/1,000 person-years for BCC. Across all cancers, all-cause mortality was associated with older patient age and male patient sex, as well as socioeconomic index.

Currently, there are few UK reports comparing the prevalence of all skin cancers prior to 2014. This study therefore provides novel data, which are likely to be representative of the UK as a whole, and provide a comparison for MM, SCC and BCC. Using the newly available data on keratinocyte skin cancers in England's cancer registry, Venables *et al*⁷ describe that in 2013-2015 the SCC incidence was 77.3 per 100,000 person-years in men and 34.1 per 100,000 person year in women. Our data supplements this work to suggest a true ongoing trend of increased cases of not only SCC, but also BCC and MM in England as well as the entire UK. A limitation of our study is that there is likely an underestimation of true tumour incidence; we attempted to attenuate this by including multiple primaries, defined as the reappearance of a skin cancer medcode after a three-year lapse. We describe incidence of MM and keratinocyte skin cancers, as well as outline the potential role of patient age, sex, and higher socioeconomic index on outcomes. Furthermore, our work suggests that current trends in incidence in other countries which do not include keratinocyte skin cancers in central cancer registries may also be assessed by similar general practice records, including the Veterans Health Project in the United States and the Electronic Medical Record Administrative Linked Database (EMRALD) and Canadian Primary Care Sentinel Surveillance Network (CPCSSN) in Canada.

References

- 1 Cancer Research UK. Available at: www.cancerresearch.org. Accessed July 2020.
- 2 Schadendorf D, Akkooi Acj, Berking C, *et al*. Melanoma. *Lancet* 2018; **392**:971–84.
- 3 Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. *Br J Dermatology* 2012; **166**:1069–80.
- 4 Doherty V, Brewster D. Trends in skin cancer incidence by socioeconomic position in Scotland, 1978–2004. *Brit J Cancer* 2010; **102**:1661–4.
- 5 Parkin D. 13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. *Brit J Cancer* 2011; **105**:S66–9.
- 6 Musah A, Gibson J, Leonardi-Bee J, *et al*. Regional variations of basal cell carcinoma incidence in the U.K. using The Health Improvement Network database (2004–10). *Brit J Dermatol* 2013; **169**:1093–9.
- 7 Venables Z, Autier P, Nijsten T, *et al*. Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England. *Jama Dermatol* 2019; **155**:298–306.

Author Manuscript

Table 1. Stratified incidence and mortality model for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM) in the UK (2004-2014) using the European Standard Population in 5-year age categories.

		BCC										SCC										MM									
Sex, Region, and Age- Stratified Incidence, 2004-2014 Per 100,000 PY (Standard Error)		M					F					M					F					M					F				
		0-19	20-39	40-59	60-79	80+	0-19	20-49	50-69	70-89	90+	0-19	20-49	50-69	70-89	90+	0-19	20-49	50-69	70-89	90+	0-19	20-49	50-69	70-89	90+	0-19	20-49	50-69	70-89	90+
Region	England	0.2 (0.06)	10.4 (0.4)	90.2 (1.2)	452.9 (3.3)	1001.2 (10.8)	0.3 (0.07)	14.1 (0.5)	99.6 (1.3)	332.9 (2.8)	588.4 (6.3)	0.1 (0.05)	1.3 (0.1)	17.1 (0.5)	127.1 (1.8)	467.5 (7.4)	0.1 (0.05)	2.0 (0.2)	12.1 (0.4)	64.7 (1.2)	221.8 (3.8)	1.6 (0.2)	7.4 (0.4)	20.0 (0.6)	47.7 (1.1)	79.7 (3.1)	1.8 (0.2)	16.3 (0.5)	27.5 (0.7)	40.1 (1.0)	48.1 (1.8)
	Wales	0.0 (0.0)	1.0 (0.4)	22.6 (1.8)	158.4 (5.5)	615.7 (24.8)	0.2 (0.2)	2.5 (0.6)	15.0 (1.4)	74.4 (3.7)	273.4 (12.4)	0.5 (0.3)	12.9 (1.4)	125.2 (4.1)	626.7 (11.0)	1316.4 (36.3)	0.4 (0.3)	14.8 (1.5)	127.2 (4.2)	423.5 (8.7)	717.9 (201)	2.1 (0.5)	6.2 (1.0)	19.3 (1.6)	50.9 (3.1)	88.1 (9.4)	1.7 (0.5)	16.7 (1.6)	24.6 (1.9)	37.6 (2.6)	45.6 (5.0)
	Scotland	0.2 (0.2)	8.2 (1.1)	72.4 (3.0)	358.9 (8.8)	909.3 (34.7)	0.3 (0.2)	10.0 (1.2)	71.1 (3.0)	252.8 (7.0)	538.0 (19.4)	0.0 (0.0)	1.4 (0.4)	15.6 (1.4)	120.1 (5.1)	460.6 (24.7)	0.0 (0.0)	1.6 (0.5)	8.2 (1.0)	56.4 (3.3)	216.0 (12.3)	1.1 (0.4)	5.9 (0.9)	16.6 (1.4)	41.9 (3.0)	83.4 (10.5)	1.9 (0.6)	14.4 (1.4)	20.9 (1.6)	31.8 (2.5)	52.9 (6.1)
	Northern Ireland	1.3 (0.8)	9.0 (1.9)	94.6 (6.1)	481.7 (18.0)	1121.9 (66.7)	0.5 (0.5)	9.9 (2.0)	83.5 (5.7)	316.9 (13.8)	654.4 (36.4)	0.0 (0.0)	2.4 (1.0)	30.1 (3.4)	206.1 (11.7)	757.3 (54.8)	0.0 (0.0)	4.9 (1.4)	18.9 (2.7)	99.7 (7.7)	405.2 (28.7)	2.7 (1.1)	10.2 (2.0)	16.4 (2.5)	57.5 (6.2)	87.2 (18.6)	1.9 (0.9)	24.6 (3.2)	33.5 (3.6)	40.6 (4.9)	66.9 (11.6)
Mortality Model† Coefficient (95% CI)	Age (Year-on- Year)	1.137 (1.133, 1.140)										1.068 (1.065, 1.072)										1.079 (1.074, 1.084)									
	Gender (Female)	0.667 (0.636, 0.699)										0.859 (0.799, 0.924)										0.629 (0.561, 0.704)									
	Index of Multiple Deprivation (Increasing Deprivation Twentiles)	1.040 (1.035, 1.045)										1.045 (1.037, 1.053)										1.033 (1.021, 1.044)									

† Values in the morality model are represented as odds ratios.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Mirza, FN;Yumeen, S;Walter, FM

Title:

The epidemiology of malignant melanoma, squamous cell carcinoma and basal cell carcinoma in the UK from 2004 to 2014: a population-based cohort analysis using the Clinical Practice Research Datalink

Date:

2020-11-24

Citation:

Mirza, F. N., Yumeen, S. & Walter, F. M. (2020). The epidemiology of malignant melanoma, squamous cell carcinoma and basal cell carcinoma in the UK from 2004 to 2014: a population-based cohort analysis using the Clinical Practice Research Datalink. BRITISH JOURNAL OF DERMATOLOGY, 184 (2), pp.365-367. <https://doi.org/10.1111/bjd.19542>.

Persistent Link:

<http://hdl.handle.net/11343/276645>